Literature DB >> 23030352

Substance of abuse and movement disorders: complex interactions and comorbidities.

Andres Deik1, Rachel Saunders-Pullman, Marta San Luciano.   

Abstract

The relationship between movement disorders and substance abuse, which we previously reviewed, is updated. We examine these relationships bidirectionally with focus on drugs of abuse that are known to cause movement disorders, as well as primary movement disorders that are associated with use and abuse of alcohol and dopaminergic medications. First, we review the movement disorders that may develop from the acute use or withdrawal of frequent drugs of abuse, including alcohol, cocaine, heroin, amphetamine and methcathinone. We then comment on the interaction between alcoholism and alcohol-responsive movement disorders, such as essential tremor and myoclonus-dystonia. Lastly, we discuss the potential for abuse of antiparkinsonian dopaminergic agents in patients with Parkinson's disease (PD).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23030352      PMCID: PMC3966544          DOI: 10.2174/1874473711205030243

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  159 in total

1.  A silent synapse-based mechanism for cocaine-induced locomotor sensitization.

Authors:  Travis E Brown; Brian R Lee; Ping Mu; Deveroux Ferguson; David Dietz; Yoshinori N Ohnishi; Ying Lin; Anna Suska; Masago Ishikawa; Yanhua H Huang; Haowei Shen; Peter W Kalivas; Barbara A Sorg; R Suzanne Zukin; Eric J Nestler; Yan Dong; Oliver M Schlüter
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

2.  Dependence on zolpidem.

Authors:  Ming-Chyi Huang; Hong-Yen Lin; Chun-Hsin Chen
Journal:  Psychiatry Clin Neurosci       Date:  2007-04       Impact factor: 5.188

Review 3.  [Understanding a new conception of addiction in current clinical practices].

Authors:  Toshihiko Matsumoto
Journal:  Nihon Arukoru Yakubutsu Igakkai Zasshi       Date:  2012-02

4.  Resting hand tremor in abstinent cocaine-dependent, alcohol-dependent, and polydrug-dependent patients.

Authors:  L O Bauer
Journal:  Alcohol Clin Exp Res       Date:  1996-10       Impact factor: 3.455

5.  Serotonin toxicity involving MDMA (ecstasy) and moclobemide.

Authors:  J L Pilgrim; D Gerostamoulos; N Woodford; Olaf H Drummer
Journal:  Forensic Sci Int       Date:  2011-05-13       Impact factor: 2.395

Review 6.  Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.

Authors:  J P Little; E B Villanueva; A Klegeris
Journal:  Mini Rev Med Chem       Date:  2011-06       Impact factor: 3.862

7.  Wine drinking and essential tremor: a possible protective role.

Authors:  Alessandra Nicoletti; Giovanni Mostile; Roberto Cappellani; Donatella Contrafatto; Gennarina Arabia; Paolo Lamberti; Roberto Marconi; Letterio Morgante; Paolo Barone; Aldo Quattrone; Mario Zappia
Journal:  Mov Disord       Date:  2011-04-19       Impact factor: 10.338

Review 8.  Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy).

Authors:  Takayuki Nakagawa; Shuji Kaneko
Journal:  J Pharmacol Sci       Date:  2008-01-16       Impact factor: 3.337

9.  A Parkinsonian syndrome in methcathinone users and the role of manganese.

Authors:  Ainārs Stepens; Ināra Logina; Viesturs Liguts; Pauls Aldins; Ilze Eksteina; Ardis Platkājis; Inese Mārtinsone; Elmārs Tērauds; Baiba Rozentāle; Michael Donaghy
Journal:  N Engl J Med       Date:  2008-03-06       Impact factor: 91.245

10.  Acute phencyclidine intoxication: clinical patterns, complications, and treatment.

Authors:  M M McCarron; B W Schulze; G A Thompson; M C Conder; W A Goetz
Journal:  Ann Emerg Med       Date:  1981-06       Impact factor: 5.721

View more
  20 in total

Review 1.  Medication-Induced Tardive Dyskinesia: A Review and Update.

Authors:  Elyse M Cornett; Matthew Novitch; Alan David Kaye; Vijay Kata; Adam M Kaye
Journal:  Ochsner J       Date:  2017

2.  The Cerebellar GABAAR System as a Potential Target for Treating Alcohol Use Disorder.

Authors:  David J Rossi; Ben D Richardson
Journal:  Handb Exp Pharmacol       Date:  2018

3.  Dystonia-Parkinsonism Due to Pallidal and Nigral Necrosis Following Heroin Overdose: Long-Term Evolution.

Authors:  Siew Lee Shu; Philip D Thompson; Thomas E Kimber
Journal:  Mov Disord Clin Pract       Date:  2015-10-01

4.  Attention bias modification in drug addiction: Enhancing control of subsequent habits.

Authors:  Muhammad A Parvaz; Pias Malaker; Anna Zilverstand; Scott J Moeller; Nelly Alia-Klein; Rita Z Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-08       Impact factor: 11.205

5.  Cocaine-induced Pisa syndrome.

Authors:  Marcello Mario Mascia; Giovanni Defazio
Journal:  Neurol Sci       Date:  2021-06-19       Impact factor: 3.307

6.  All Trans Retinoic Acid Attenuates Markers of Neuroinflammation in Rat Brain by Modulation of SIRT1 and NFκB.

Authors:  S H Priyanka; S Syam Das; A J Thushara; Arun A Rauf; M Indira
Journal:  Neurochem Res       Date:  2018-07-18       Impact factor: 3.996

7.  Heroin abuse exaggerates age-related deposition of hyperphosphorylated tau and p62-positive inclusions.

Authors:  Gabor G Kovacs; Monika Cs Horvath; Katalin Majtenyi; Mirjam I Lutz; Yasmin L Hurd; Eva Keller
Journal:  Neurobiol Aging       Date:  2015-07-17       Impact factor: 4.673

Review 8.  [Alcohol induced cognitive deficits].

Authors:  Elisabeth Weiss; Evelin M Singewald; Beatrix Ruepp; Josef Marksteiner
Journal:  Wien Med Wochenschr       Date:  2013-07-19

9.  Puerarin protects against damage to spatial learning and memory ability in mice with chronic alcohol poisoning.

Authors:  S Q Cui; Q Wang; Y Zheng; B Xiao; H W Sun; X L Gu; Y C Zhang; C H Fu; P X Dong; X M Wang
Journal:  Braz J Med Biol Res       Date:  2015-03-27       Impact factor: 2.590

Review 10.  Psychostimulants and movement disorders.

Authors:  Andres Asser; Pille Taba
Journal:  Front Neurol       Date:  2015-04-20       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.